Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Exclusion Criteria

• •Prior chemotherapy or adjuvant chemotherapy for the treatment of lung cancer.
• •Prior treatment with cetuximab or other epidermal growth factor (EGFR)-targeted therapy.
• •Prior severe infusion reaction to antibody therapy.
• •Concurrent malignancy (previous malignancy without evidence of disease for 5 years will be allowed to enter trial).
• •Concurrent chemotherapy or therapy with another investigational agent not indicated in the protocol.
• •Serious uncontrolled medical disorders that would impair the ability to receive therapy.
• •History of myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure.
• •Peripheral neuropathy \>= grade 2 (Common Toxicity Criteria Adverse Event \[CTCAE\] Version 3.0).
• •Inadequate hematologic and/or liver and/or kidney function.
• •Sexually active and fertile individuals or partners of these individuals who are unwilling or unable to use an acceptable method of birth control for entire trial and up to 4 weeks after the study.
• •Women who are pregnant or breastfeeding.
• •Women with a positive pregnancy test on enrollment prior to study drug administration.
• •Altered mental status or psychiatric condition that prohibits understanding or rendering of consent.